These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37730609)
1. Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer. Navarro-Domenech I; Arulanantham S; Liu ZA; Tjong M; Kong V; Malkov V; Tadic T; Fleshner N; Kulkarni G; Zlotta AR; Catton C; Berlin A; Sridhar S; Jiang DM; Chung P; Raman S Radiat Oncol; 2023 Sep; 18(1):154. PubMed ID: 37730609 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial. Fonteyne V; Dirix P; Van Praet C; Berghen C; Albersen M; Junius S; Liefhooghe N; Noé L; De Meerleer G; Ost P; Villeirs G; Verbeke S; De Maeseneer D; Rammant E; Verghote F; Elhaseen E; De Man K; Decaestecker K Eur Urol Focus; 2022 Sep; 8(5):1238-1245. PubMed ID: 34893458 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study. Orré M; Latorzeff I; Fléchon A; Roubaud G; Brouste V; Gaston R; Piéchaud T; Richaud P; Chapet O; Sargos P PLoS One; 2017; 12(4):e0174978. PubMed ID: 28384195 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes? Hurmuz P; Ozyigit G; Kilickap S; Esen CSB; Akdogan B; Ozen H; Akyol F Urol Oncol; 2021 Jun; 39(6):368.e19-368.e29. PubMed ID: 33189528 [TBL] [Abstract][Full Text] [Related]
5. [Image-guided radiotherapy for muscle invasive bladder cancer with intravesical lipiodol injection. A new option for bladder sparing treatment]. Kliton J; Polgár C; Tenke P; Kovács G; Major T; Stelczer G; Ágoston P Orv Hetil; 2017 Dec; 158(51):2041-2047. PubMed ID: 29250970 [TBL] [Abstract][Full Text] [Related]
11. High-precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-day Integrated Boost Technique with Image Guidance Using Lipiodol Markers. Beulens AJW; van der Toorn PP; de Wildt MJ; Scheepens WA Eur Urol Oncol; 2019 Feb; 2(1):39-46. PubMed ID: 30929845 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. Fonteyne V; Dirix P; Junius S; Rammant E; Ost P; De Meerleer G; Swimberghe M; Decaestecker K BMC Cancer; 2017 May; 17(1):308. PubMed ID: 28464906 [TBL] [Abstract][Full Text] [Related]
13. [The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis]. Zhong SJ; Gao JJ; Tang P; Liu YP; Wang SL; Fang H; Qiu JP; Song YW; Chen B; Qi SN; Tang Y; Lu NN; Jing H; Zhai YR; Zhou AP; Bi XG; Ma JH; Li CL; Zhang Y; Shou JZ; Xing NZ; Li YX Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):175-181. PubMed ID: 36781240 [No Abstract] [Full Text] [Related]
14. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956 [TBL] [Abstract][Full Text] [Related]
15. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678 [TBL] [Abstract][Full Text] [Related]
18. Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long-term Outcomes With Dose Escalation. Murthy V; Gupta P; Baruah K; Krishnatry R; Joshi A; Prabhash K; Noronha V; Menon S; Pal M; Prakash G; Bakshi G Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):646-652. PubMed ID: 31301959 [TBL] [Abstract][Full Text] [Related]
19. Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer. Youssief Mohammed AA; Gamal DA; Abd Elzaher AR; Hasaballah A Asian Pac J Cancer Prev; 2023 Feb; 24(2):517-524. PubMed ID: 36853300 [TBL] [Abstract][Full Text] [Related]
20. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Chahal R; Sundaram SK; Iddenden R; Forman DF; Weston PM; Harrison SC Eur Urol; 2003 Mar; 43(3):246-57. PubMed ID: 12600427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]